AusperBio has raised $63 million in Series B2 financing, led by Qiming Venture Partners, to advance its AHB-137 product for chronic hepatitis B therapies.
Amount Raised
$63 Million
Round Type
Series B
Investors
Description
AusperBio Therapeutics, Inc. announced the closing of its $63 million Series B2 financing, supported by existing investors. The round was co-led by Qiming Venture Partners with participation from several others. Proceeds will advance the clinical development of AHB-137 and other key initiatives
Quick answer
AusperBio raised $63 Million in a Series B round, dated September 22, 2025. Investors: CDH Investments, Hankang Capital, Yuanbio Venture Capital, Genesis Capital, Sherpa Capital and Qiming Venture Partners.
- How much did AusperBio raise?
- AusperBio raised $63 Million in a Series B round on September 22, 2025.
- Who invested in AusperBio?
- CDH Investments, Hankang Capital, Yuanbio Venture Capital, Genesis Capital, Sherpa Capital and Qiming Venture Partners are named as investors in this round.
- What does AusperBio do?
- AusperBio is a clinical-stage biopharmaceutical company with operations in the USA and China, dedicated to advancing oligonucleotide and targeted delivery technologies for transformative therapies, with an initial focus..
- Where is AusperBio based and how big is it?
- Fundz records about 100 employees.
- Who are the decision-makers at AusperBio?
- Fundz holds 4 contacts at AusperBio, including the Co-Founder & CEO. Names and contact details are shown to Fundz members.
Source: Fundz verified event record.
Who else raised in Therapeutics and Biopharma around the same time
Companies in the same sectors as AusperBio that raised within 45 days of this round, from Fundz verified event records.
- Acasti raised $4M (Funding Round) on October 23, 2025.
- Minerva Neurosciences raised $200M (Funding Round) on October 21, 2025.
- Theriva Biologics raised $13M on October 17, 2025.
- Theriva Biologics raised $4M (Funding Round) on October 16, 2025.
- ISOThrive raised $8.1M on October 10, 2025.
- TORL BioTherapeutics raised $96M (Series C) on October 7, 2025.
Who to call at AusperBio, and when
A new round usually means AusperBio is about to hire and buy. The teams that reach out first get the meeting.
- An alert the day AusperBio raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at AusperBio, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at AusperBio. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment AusperBio raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Funding Insights
What this usually meansAusperBio raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.